See also: Generic Flagyl
Flagyl ER is a brand name of metronidazole, approved by the FDA in the following formulation(s):
FLAGYL ER (metronidazole - tablet, extended release; oral)
Manufacturer: GD SEARLE LLC
Approval date: November 26, 1997
Strength(s): 750MG [RLD][AB]
Has a generic version of Flagyl ER been approved?
A generic version of Flagyl ER has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Flagyl ER and have been approved by the FDA:
metronidazole tablet, extended release; oral
Manufacturer: ALEMBIC LTD
Approval date: May 5, 2010
Strength(s): 750MG [AB]
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Flagyl ER. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Modified-release metronidazole compositions and methods for making and using same
Patent 6,103,262
Issued: August 15, 2000
Inventor(s): Desai; Subhash & Mancini; Alan Mark & Schumann; Steven Charles
Assignee(s): G. D. Searle & Company
Pharmaceutical compositions having a modified release profile for once daily dosing of metronidazole, methods for making the pharmaceutical compositions, and methods for treating a microbial infection with once daily dosing of the pharmaceutical compositions of the invention are provided. The compositions given once daily exhibit substantial bioequivalence to immediate release metronidazole given three times per day. The compositions of the invention comprise: (a) a first portion of metronidazole which is about 59 wt % to about 79 wt % metronidazole; (b) about 1.5 wt % to about 3.0 wt % of an aqueous insoluble poly(meth)acrylic acid ester copolymer which is aqueous permeable, aqueous expandable and pH-independent; (c) about 0.1 wt % to about 2.0 wt % detackifier; (d) 0 to about 23 wt % of a first aqueous soluble pharmaceutical diluent; (e) 0 to about 23 wt % of a second aqueous soluble diluent which is suitable for forming a pharmaceutical tablet when compressed with the granules of (a), the second aqueous soluble diluent being the same as or different from the first aqueous soluble diluent; (f) 0 to about 20 wt % of a second portion of metronidazole; (g) 0 to about 0.2 wt % glidant; and (h) 0 to about 2 wt % lubricant; wherein the composition comprises metronidazole containing granules comprising (a), (b), (c) and (d), wherein the sum of the weight percentages of metronidazole provided by (a) and (f) is between about 72 wt % and about 79 wt %, and wherein the sum of the weight percentages of the aqueous soluble diluent provided by (d) and (e) is between about 16 wt % and about 23 wt %.
Patent expiration dates:
See also...
- Flagyl ER Extended-Release Tablets Consumer Information (Wolters Kluwer)
- Flagyl ER Consumer Information (Cerner Multum)
- Flagyl ER Advanced Consumer Information (Micromedex)
- Metronidazole Consumer Information (Drugs.com)
- Metronidazole Consumer Information (Wolters Kluwer)
- Metronidazole Capsules Consumer Information (Wolters Kluwer)
- Metronidazole Extended-Release Tablets Consumer Information (Wolters Kluwer)
- Metronidazole Tablets Consumer Information (Wolters Kluwer)
- Metronidazole Consumer Information (Cerner Multum)
- Flagyl I.V. RTU Advanced Consumer Information (Micromedex)
- Flagyl I.V. RTU Intravenous Advanced Consumer Information (Micromedex)
- Metronidazole Intravenous Advanced Consumer Information (Micromedex)
- Metronidazole Oral, Intravenous Advanced Consumer Information (Micromedex)
- Metronidazole AHFS DI Monographs (ASHP)
- Metronidazole Hydrochloride AHFS DI Monographs (ASHP)
